CCL5/RANTES在慢性肝病期间肝细胞癌进展中的功能作用
本研究在慢性肝病患者及两种小鼠炎症相关肝细胞癌模型中探讨CCL5的作用,发现慢性肝病患者CCL5及其受体CCR5过表达,CCL5缺失可减轻小鼠肝细胞凋亡、代偿性增殖和纤维化,减少免疫细胞浸润,一年龄NEMOΔhepa/CCL5-/-小鼠肿瘤更小且恶性程度更低,Evasin-4干预8周可改善肝病进展。
要点
- 慢性肝病患者中CCL5及其受体CCR5过表达。
- CCL5缺失减轻小鼠肝细胞凋亡、代偿性增殖和纤维化。
- Evasin-4干预8周可改善小鼠肝病进展。
核心结论
- CCL5在人类和小鼠慢性肝病进展尤其是肝细胞癌发生中起重要作用,体内抑制CCL5对慢性肝病患者似乎令人鼓舞。
研究设计与样本
- 研究在明确诊断的慢性肝病患者和两种小鼠炎症相关肝细胞癌模型中检测CCL5及其受体表达。
- 在NEMOΔhepa/CCL5-/-动物不同细胞群及骨髓移植后分析CCL5在炎症、纤维化、肿瘤起始和进展中的作用。
- 治疗干预中注射Evasin-4持续24小时或8周。
主要发现
- 慢性肝病患者中CCL5及其受体CCR5过表达,Mdr2-/-和NEMOΔhepa模型中也证实此观察。
- NEMOΔhepa小鼠中CCL5缺失因免疫细胞浸润减少而减轻肝细胞凋亡、代偿性增殖和纤维化。
- CD45+/Ly6G+粒细胞、CD45+/CD11b+/Gr1.1+/F4/80+促炎单核细胞、CD4+和CD8+ T细胞减少。
- 一年龄NEMOΔhepa/CCL5-/-小鼠肿瘤更小且恶性程度更低,表现为增殖能力降低和血管生成减少。
- 造血细胞被鉴定为CCL5的主要来源,CCL5缺失未使NEMOΔhepa肝细胞对TNFα诱导的凋亡敏感。
临床怎么用
- 作者认为,体内抑制CCL5对慢性肝病患者似乎令人鼓舞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: During liver inflammation, triggering fibrogenesis and carcinogenesis immune cells play a pivotal role. In the present study we investigated the role of CCL5 in human and in murine models of chronic liver inflammation leading to hepatocellular carcinoma (HCC) development. METHODS: CCL5 expression and its receptors were studied in well-defined patients with chronic liver disease (CLD) and in two murine inflammation based HCC models. The role of CCL5 in inflammation, fibrosis, tumor initiation and progression was analyzed in different cell populations of NEMOΔhepa/CCL5-/- animals and after bone marrow transplantation (BMT). For therapeutic intervention Evasin-4 was injected for 24h or 8weeks. RESULTS: In CLD patients, CCL5 and its receptor CCR5 are overexpressed - an observation confirmed in the Mdr2-/- and NEMOΔhepa model. CCL5 deletion in NEMOΔhepa mice diminished hepatocyte apoptosis, compensatory proliferation and fibrogenesis due to reduced immune cell infiltration. Especially, CD45+/Ly6G+ granulocytes, CD45+/CD11b+/Gr1.1+/F4/80+ pro-inflammatory monocytes, CD4+ and CD8+ T cells were decreased. One year old NEMOΔhepa/CCL5-/- mice displayed smaller and less malignant tumors, characterized by reduced proliferative capacity and less pronounced angiogenesis. We identified hematopoietic cells as the main source of CCL5, while CCL5 deficiency did not sensitise NEMOΔhepa hepatocytes towards TNFα induced apoptosis. Finally, therapeutic intervention with Evasin-4 over a period of 8weeks ameliorated liver disease progression. CONCLUSION: We identified an important role of CCL5 in human and functionally in mice with disease progression, especially HCC development. A novel approach to inhibit CCL5 in vivo thus appears encouraging for patients with CLD. LAY SUMMARY: Our present study identifies the essential role of the chemoattractive cytokine CCL5 for liver disease progression and especially hepatocellular carcinoma development in men and mice. Finally, the inhibition of CCL5 appears to be encouraging for therapy of human chronic liver disease.
引用
- Mohs A, Kuttkat N, Reißing J, et al. Functional role of CCL5/RANTES for HCC progression during chronic liver disease. J Hepatol. 2016. PMID: 28011329. doi:10.1016/j.jhep.2016.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。